ArticleThe Lancet regional health. Western Pacific2022

Safety and immunogenicity of Nanocovax, a SARS-CoV-2 recombinant spike protein vaccine: Interim results of a double-blind, randomised controlled phase 1 and 2 trial.

Thuy P Nguyen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.